Royo-Cebrecos, CristinaLaporte-Amargós, JuliaPeña, MartaRuiz-Camps, IsabelPuerta-Alcalde, PedroAbdala, EdsonOltolini, ChiaraAkova, MuratMontejo, MiguelMikulska, MalgorzataMartín-Dávila, PilarHerrera, FabianGasch, OriolDrgona, LubosMorales, Hugo Manuel PazBrunel, Anne-SophieGarcía, EstefaníaIsler, BurcuKern, Winfried VPalacios-Baena, Zaira Rde la Calle, Guillermo MaestroMontero, Maria MilagroKanj, Souha SSipahi, Oguz RCalik, SebnemMárquez-Gómez, IgnacioMarin, Jorge IGomes, Marisa Z RHemmatti, PhilippAraos, RafaelPeghin, MaddalenaDel Pozo, José LuisYáñez, LucreciaTilley, RobertManzur, AdrianaNovo, AndrésCarratalà, JordiGudiol, CarlotaIRONIC study group2023-05-032023-05-032022-09-302076-0817http://hdl.handle.net/10668/21531Objectives: To assess the clinical features and outcomes of Pseudomonas aeruginosa bloodstream infection (PA BSI) in neutropenic patients with hematological malignancies (HM) and with solid tumors (ST), and identify the risk factors for 30-day mortality. Methods: We performed a large multicenter, retrospective cohort study including onco-hematological neutropenic patients with PA BSI conducted across 34 centers in 12 countries (January 2006−May 2018). Episodes occurring in hematologic patients were compared to those developing in patients with ST. Risk factors associated with 30-day mortality were investigated in both groups. Results: Of 1217 episodes of PA BSI, 917 occurred in patients with HM and 300 in patients with ST. Hematological patients had more commonly profound neutropenia (0.1 × 109 cells/mm) (67% vs. 44.6%; penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Pseudomonas aeruginosabacteremiabloodstream infectioncancerhematologic malignancysolid tumorresearch article36297188open access10.3390/pathogens11101132PMC9610728https://www.mdpi.com/2076-0817/11/10/1132/pdf?version=1664533122https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610728/pdf